# Lactobacillus Bifidobacterium V9(Kex02)Improving the Efficacy of Carilizumab Combined With Platinum in Non-small Cell Lung Cancer Patients

> **NCT05094167** · NA · UNKNOWN · sponsor: **Jiangxi Provincial Cancer Hospital** · enrollment: 46 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **OTHER:** V9
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT05094167
- **Lead sponsor:** Jiangxi Provincial Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-19
- **Primary completion:** 2022-12-27
- **Final completion:** 2023-12-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2021-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05094167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05094167, "Lactobacillus Bifidobacterium V9(Kex02)Improving the Efficacy of Carilizumab Combined With Platinum in Non-small Cell Lung Cancer Patients". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT05094167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*